产前服用硫酸镁与产后出血之间的关系。

IF 0.8 Q4 PEDIATRICS
AJP Reports Pub Date : 2021-01-01 Epub Date: 2021-02-01 DOI:10.1055/s-0040-1721671
Emily M S Miller, Allie Sakowicz, Elise Leger, Elizabeth Lange, Lynn M Yee
{"title":"产前服用硫酸镁与产后出血之间的关系。","authors":"Emily M S Miller, Allie Sakowicz, Elise Leger, Elizabeth Lange, Lynn M Yee","doi":"10.1055/s-0040-1721671","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective</b>  The aim of the study is to investigate the association between intrapartum administration of magnesium sulfate in women with hypertensive disorders of pregnancy and postpartum hemorrhage. <b>Study Design</b>  This was a retrospective cohort study of women diagnosed with a hypertensive disorder of pregnancy who delivered singleton gestations >32 weeks at a single, large volume tertiary care center between January 2006 and February 2015. Women who received intrapartum magnesium sulfate for seizure prophylaxis were compared with women who did not receive intrapartum magnesium sulfate. The primary outcome was frequency of postpartum hemorrhage. Secondary outcomes included estimated blood loss, uterine atony, and transfusion of packed red blood cells. Bivariable analyses were used to compare the frequencies of each outcome. Multivariable logistic regression models examined the independent associations of magnesium sulfate with outcomes. <b>Results</b>  Of 2,970 women who met inclusion criteria, 1,072 (36%) received intrapartum magnesium sulfate. Women who received magnesium sulfate were more likely to be nulliparous, publicly insured, of minority race or ethnicity, earlier gestational age at delivery, and undergo labor induction. The frequency of postpartum hemorrhage was significantly higher among women who received magnesium sulfate compared with those who did not (12.4 vs. 9.3%, <i>p</i>  = 0.008), which persisted after controlling for potential confounders. Of secondary outcomes, there was no difference in estimated blood loss between women who did and did not receive magnesium sulfate (250 mL [interquartile range 250-750] vs. 250 mL [interquartile range 250-750], <i>p</i>  = 0.446). However, compared with women who did not receive magnesium sulfate, women who received magnesium sulfate had a greater frequency of uterine atony (8.9 vs 4.9%, <i>p</i>  < 0.001) and transfusion of packed red blood cells (2.0 vs. 0.8%, <i>p</i>  = 0.008). These differences persisted after controlling for potential confounders. <b>Conclusion</b>  Intrapartum magnesium sulfate administration to women with hypertensive disorders of pregnancy is associated with increased odds of postpartum hemorrhage, uterine atony, and red blood cell transfusion.</p>","PeriodicalId":7645,"journal":{"name":"AJP Reports","volume":"11 1","pages":"e21-e25"},"PeriodicalIF":0.8000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/66/10-1055-s-0040-1721671.PMC7850913.pdf","citationCount":"0","resultStr":"{\"title\":\"Association between Receipt of Intrapartum Magnesium Sulfate and Postpartum Hemorrhage.\",\"authors\":\"Emily M S Miller, Allie Sakowicz, Elise Leger, Elizabeth Lange, Lynn M Yee\",\"doi\":\"10.1055/s-0040-1721671\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective</b>  The aim of the study is to investigate the association between intrapartum administration of magnesium sulfate in women with hypertensive disorders of pregnancy and postpartum hemorrhage. <b>Study Design</b>  This was a retrospective cohort study of women diagnosed with a hypertensive disorder of pregnancy who delivered singleton gestations >32 weeks at a single, large volume tertiary care center between January 2006 and February 2015. Women who received intrapartum magnesium sulfate for seizure prophylaxis were compared with women who did not receive intrapartum magnesium sulfate. The primary outcome was frequency of postpartum hemorrhage. Secondary outcomes included estimated blood loss, uterine atony, and transfusion of packed red blood cells. Bivariable analyses were used to compare the frequencies of each outcome. Multivariable logistic regression models examined the independent associations of magnesium sulfate with outcomes. <b>Results</b>  Of 2,970 women who met inclusion criteria, 1,072 (36%) received intrapartum magnesium sulfate. Women who received magnesium sulfate were more likely to be nulliparous, publicly insured, of minority race or ethnicity, earlier gestational age at delivery, and undergo labor induction. The frequency of postpartum hemorrhage was significantly higher among women who received magnesium sulfate compared with those who did not (12.4 vs. 9.3%, <i>p</i>  = 0.008), which persisted after controlling for potential confounders. Of secondary outcomes, there was no difference in estimated blood loss between women who did and did not receive magnesium sulfate (250 mL [interquartile range 250-750] vs. 250 mL [interquartile range 250-750], <i>p</i>  = 0.446). However, compared with women who did not receive magnesium sulfate, women who received magnesium sulfate had a greater frequency of uterine atony (8.9 vs 4.9%, <i>p</i>  < 0.001) and transfusion of packed red blood cells (2.0 vs. 0.8%, <i>p</i>  = 0.008). These differences persisted after controlling for potential confounders. <b>Conclusion</b>  Intrapartum magnesium sulfate administration to women with hypertensive disorders of pregnancy is associated with increased odds of postpartum hemorrhage, uterine atony, and red blood cell transfusion.</p>\",\"PeriodicalId\":7645,\"journal\":{\"name\":\"AJP Reports\",\"volume\":\"11 1\",\"pages\":\"e21-e25\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/66/10-1055-s-0040-1721671.PMC7850913.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AJP Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0040-1721671\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/2/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJP Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0040-1721671","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

摘要

研究目的 研究妊娠高血压疾病妇女产前服用硫酸镁与产后出血之间的关系。研究设计 这是一项回顾性队列研究,研究对象是 2006 年 1 月至 2015 年 2 月期间在一家大型三级医疗中心分娩的妊娠期大于 32 周的单胎妊娠妇女。研究人员将接受产前硫酸镁预防癫痫发作的产妇与未接受产前硫酸镁预防癫痫发作的产妇进行了比较。主要结果是产后出血频率。次要结果包括估计失血量、子宫失弛缓和输注包装红细胞。二变量分析用于比较每种结果的发生频率。多变量逻辑回归模型检验了硫酸镁与结果之间的独立关联。结果 在符合纳入标准的 2,970 名产妇中,1,072 人(36%)接受了产前硫酸镁治疗。接受硫酸镁治疗的产妇更有可能是非妊娠、有公共保险、少数种族或族裔、分娩时胎龄较小、接受过引产手术。与未服用硫酸镁的产妇相比,服用硫酸镁的产妇产后出血的频率明显更高(12.4% 对 9.3%,P = 0.008),在控制了潜在的混杂因素后,这种情况依然存在。在次要结果中,接受和未接受硫酸镁治疗的妇女在估计失血量方面没有差异(250 mL [四分位间范围 250-750] vs. 250 mL [四分位间范围 250-750], p = 0.446)。然而,与未接受硫酸镁治疗的妇女相比,接受硫酸镁治疗的妇女发生子宫失弛缓的频率更高(8.9% 对 4.9%,P = 0.008)。在控制了潜在的混杂因素后,这些差异依然存在。结论 患有妊娠高血压疾病的妇女在产前服用硫酸镁与产后出血、子宫收缩和输红细胞的几率增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between Receipt of Intrapartum Magnesium Sulfate and Postpartum Hemorrhage.

Objective  The aim of the study is to investigate the association between intrapartum administration of magnesium sulfate in women with hypertensive disorders of pregnancy and postpartum hemorrhage. Study Design  This was a retrospective cohort study of women diagnosed with a hypertensive disorder of pregnancy who delivered singleton gestations >32 weeks at a single, large volume tertiary care center between January 2006 and February 2015. Women who received intrapartum magnesium sulfate for seizure prophylaxis were compared with women who did not receive intrapartum magnesium sulfate. The primary outcome was frequency of postpartum hemorrhage. Secondary outcomes included estimated blood loss, uterine atony, and transfusion of packed red blood cells. Bivariable analyses were used to compare the frequencies of each outcome. Multivariable logistic regression models examined the independent associations of magnesium sulfate with outcomes. Results  Of 2,970 women who met inclusion criteria, 1,072 (36%) received intrapartum magnesium sulfate. Women who received magnesium sulfate were more likely to be nulliparous, publicly insured, of minority race or ethnicity, earlier gestational age at delivery, and undergo labor induction. The frequency of postpartum hemorrhage was significantly higher among women who received magnesium sulfate compared with those who did not (12.4 vs. 9.3%, p  = 0.008), which persisted after controlling for potential confounders. Of secondary outcomes, there was no difference in estimated blood loss between women who did and did not receive magnesium sulfate (250 mL [interquartile range 250-750] vs. 250 mL [interquartile range 250-750], p  = 0.446). However, compared with women who did not receive magnesium sulfate, women who received magnesium sulfate had a greater frequency of uterine atony (8.9 vs 4.9%, p  < 0.001) and transfusion of packed red blood cells (2.0 vs. 0.8%, p  = 0.008). These differences persisted after controlling for potential confounders. Conclusion  Intrapartum magnesium sulfate administration to women with hypertensive disorders of pregnancy is associated with increased odds of postpartum hemorrhage, uterine atony, and red blood cell transfusion.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AJP Reports
AJP Reports PEDIATRICS-
CiteScore
2.20
自引率
0.00%
发文量
30
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信